Anti-Alcoholism Drug from 1950s Shows Promise in Treating Mesothelioma

An FDA-approved drug used since the 1950s to treat alcoholism has shown considerable promise in suppressing the spread of mesothelioma and enhancing the effectiveness of chemotherapy, according to a recently published study. Scientists and clinicians conducted the study, published April 2014 in PLOS ONE, to examine the effects of copper-enhanced disulfiram (DSF-Cu) on malignant pleural mesothelioma cells in vitro and on animal models. Arun K. Rishi, Ph.D., of the Karmanos Cancer Institute at Wayne State University, said the findings could clear a path to more effective treatment options for the cancer caused almost exclusively by exposure to asbestos fibers. "A drug like this could have the potential to localize the disease and prevent its spread," Rishi told Asbestos.com. "That's very exciting." Long-time mesothelioma specialist Harvey Pass, M.D., director of thoracic surgery at New York University Medical Center, also co-authored the study. Effective against Other Cancers Previous studies had shown the effectiveness of disulfiram against breast, lung and colon cancer cells, leading to the anticipation of positive results with mesothelioma. The next step before possible approval by the U.S. Food and Drug Administration (FDA) for the treatment of mesothelioma would be a Phase I clinical trial. Disulfiram, which is sold under the brand name Antabuse, works in the treatment of alcoholism on a molecular level by changing the way alcohol is metabolized...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Treatment & Doctors Source Type: news

Related Links:

Gantumur Battogtokh, Yong-Yeon Cho, Joo Young Lee, Hye Suk Lee, Han Chang Kang
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
CONCLUSION: Women receiving perinatal depression treatment experience unique parenting challenges and desire parenting support. Healthcare providers caring for these women should be mindful of their patients' parenting needs. Future research should explore ways to integrate parenting interventions with depression treatments. Mother-infant interaction is a key determinant of optimal infant development and integrating parenting support with perinatal depression treatments can have significant public health impact. PMID: 30111227 [PubMed - as supplied by publisher]
Source: Journal of Psychosomatic Obstetrics and Gynaecology - Category: OBGYN Tags: J Psychosom Obstet Gynaecol Source Type: research
PANCREATIC cancer symptoms can include weight loss, fatigue and poor digestion. But you could also be at risk of the deadly disease if your stools look like this, revealed ITV This Morning's Dr Zoe Williams. What does a healthy poo look like?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Oncol Res Treat
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
Authors: Saud B, Paudel G Abstract Air pollution has been a major problem of 21st century for both developed and developing world. It has a negative impact on various environmental aspects which directly or indirectly affect the quality of human health. Nepal, especially Kathmandu, in the current situation, is observing rapid urbanization and various infrastructure development projects. As a result, these sorts of human activities have been responsible for increasing air pollution in an enormous rate inside Kathmandu Valley. Chronic exposure of deteriorated air increases the chance of Noncommunicable Disease (NCD) ...
Source: Journal of Environmental and Public Health - Category: Environmental Health Tags: J Environ Public Health Source Type: research
Advanced stage neuroblastoma is a very aggressive pediatric cancer with limited treatment options and a high mortality rate. Glycogen synthase kinase-3β (GSK-3β) is a potential therapeutic target in neuroblastoma. Using immunohistochemical staining, we observed positive GSK-3β expression in 67% of human neuroblastomas (34 of 51 cases). Chemically distinct GSK-3 inhibitors (AR-A014418, TDZD-8, and 9-ING-41) suppressed the growth of neuroblastoma cells, whereas 9-ING-41, a clinically relevant small-molecule GSK-3β inhibitor with broad-spectrum preclinical antitumor activity, being the most potent. Inhibit...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
Long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) functions as a crucial regulator of metastasis in lung cancer. The aim of this study is to unravel the underlying mechanisms of lncRNA MALAT1 in non-small-cell lung cancer (NSCLC). A cohort of 36 NSCLC tumor tissues and adjacent normal tissues was collected postoperatively from patients with NSCLC. qRT-PCR was performed to detect the expression of MALAT1 in both NSCLC tissues and cell lines. Cell migration and invasion were monitored by wound healing assay and transwell invasion assay. Western blot was used to detect the expression ...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
In this study, MAP30, a ribosome-inactivating protein reported to have apoptotic effects on cancer cells, was fused with S3, an epidermal growth factor receptor (EGFR)-targeting peptide. In addition, CsA was used to investigate whether it can further promote the apoptotic effects of S3 fused MAP30 (MAP30–S3). Our result showed that the internalization of FITC-labeled MAP30–S3 was increased significantly by S3 in HeLa cells. Unexpectedly, MAP30–S3 only showed a minor decrease in the viability of EGFR-overexpressing cancer cells, including HeLa, SMMC-7721, and MGC803 (IC50>5 μmol/l). However, 2...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
In this study, we showed that celastrol combined with EGFR-TKIs significantly suppressed cell invasion of lung cancer cells with a T790M mutation by suppressing the EGFR pathway. Combined therapy with celastrol and EGFR-TKIs inhibited tumor growth in vivo. Together, these results suggested that combined therapy with EGFR-TKIs and celastrol may be a more effective treatment of patients with non-small-cell lung cancer with T790M mutations of the EGFR.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
In conclusion, our data not only demonstrate the potential clinical application of Rg1 as a novel chemotherapeutic candidate but also offer a mechanism-based therapeutic option by which DNA-damaging agents can be used in combination with Rg1 to target HB.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
More News: Alcoholism | Asbestosis | Cancer | Cancer & Oncology | Cancer Therapy | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Colon Cancer | Colorectal Cancer | Depression | Environmental Health | Food and Drug Administration (FDA) | Headache | Laboratory Medicine | Mesothelioma | New York University | Nicotine | Study | Suicide | Toxicology